Endurobol (GW-501516) Enhancer ID 82
GW501516 is a substance that triggers a similar response from the body as exercise. It is being investigated as a potential treatment for a range of conditions typically associated with poor diet and a lack of physical fitness.
Trials of the drug (provisionally named GW501516) by GlaxoSmithKline were never successfully completed, thus the effects of the substance on humans are not yet fully understood.
A study involving tests on mice has shown that, in combination with AICAR, the capacity for exertion and burning fat was greatly increased but it also found a correlation between GW501516 and polyp growth. While research continues, a similar prevalence in humans cannot yet be established.
If the capacity of mice to do exercise is significantly increased even without any physical training, the advantages of an extrapolation to human athletes are obvious.
Having assumed the risks of abusing an unlicensed, relatively obscure drug, an athlete could expect to lose body fat at the same time as enhancing his or her performance.
Since the product is not legally available, "Endurobol" is not an official trade name.
In April 2013, the first positive tests in cycling became known as a result of the successful development of a test by an anti-doping laboratory in Cologne, Germany.
|Ubeto positive||Positive test||16/04/2013|
|Kaikov positive||Positive test||17/03/2013|
- WADA issues alert on GW501516, World Anti-Doping Agency, accessed 21/03/2013
- Anti-doping agency warns athletes of black market drug, New Scientist, accessed 26/03/2013
- GW501516 (definition), Wikipedia, accessed 11/04/2013
- GW501516 positives confirmed, three of four riders are from same BCR Pizza Hut team, VeloNation, accessed 15/04/2013